Simulations Plus, Inc. engages in the provision of software and consulting services supporting drug discovery, development, research, clinical trial operations, regulatory submissions, and commercialization. The company is headquartered in Research Triangle Park, North Carolina and currently employs 212 full-time employees. The firm helps its clients by accelerating the discovery, development, and commercialization of pharmaceuticals and other products through science-based software and consulting solutions. The Company’s segments include Software and Services. The firm's Software segment supports pharmaceutical research, development, and commercialization through simulation, modeling, and AI-driven prediction. Its main products include GastroPlus, ADMET Predictor, MonolixSuite, and others for disease modeling and training, as well as Pro-ficiency for clinical operations. Its Services segment includes advanced consulting services across the entire drug development lifecycle. Its scientists and engineers specialize in drug discovery, pharmacokinetics, pharmacodynamics, drug modeling, clinical trial data analysis, regulatory strategy, and medical communications.
最新の財務諸表(Form-10K)によると、Simulations Plus Incの総資産は$0で、純損失は$0です。
SLPの主要な財務比率は何ですか?
Simulations Plus Incの流動比率は0、純利益率は0、1株当たり売上高は$0です。
Simulations Plus Incの収益はセグメントまたは地域別にどのように分けられていますか?
Simulations Plus Inc の最大収益セグメントは Pathogen-specific Bacteriophage Therapeutics で、最新の利益発表における収益は 4,904,000 です。地域別に見ると、United States and Australia が Simulations Plus Inc の主要市場であり、収益は 4,904,000 です。